Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Ismail Hweija"'
Autor:
Aliya A. Khan, Hajar AbuAlrob, Iman M’Hiri, Dalal S. Ali, Karel Dandurand, Hosay Said, Hisham Alkassem, Yasser Hakami, Ismail Hweija, Salman Iqbal, Mihai Romanovschi, Shehryar Mehmood, Heather Zariffeh, Gordon Guyatt, Quazi Ibrahim, Romina Brignardello-Petersen, Hamza I. Syed
Publikováno v:
Endocrine. 80:647-657
Introduction Denosumab is an effective antiresorptive molecule and reduces the risk of fracture in postmenopausal osteoporosis. Cessation of denosumab therapy however is associated with rapid declines in bone mineral density (BMD), rises in bone remo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a77e1fa48cdd6f72901945f00f26b289
https://doi.org/10.1007/s12020-022-03230-5
https://doi.org/10.1007/s12020-022-03230-5
Autor:
Aliya A. Khan, Hajar AbuAlrob, Iman M’Hiri, Dalal S. ALI, Karel Dandurand, Hosay Said, Hisham Alkassem, Yasser Hakami, Ismail Hweija, Salman Iqbal, Mihai Radu Romanovschi, Shehryar Mehmood, Heather Zariffeh, Gordon Guyatt, Quazi Ibrahim, Romina Brignardello-Petersen
Introduction: Denosumab is an effective antiresorptive molecule and reduces the risk of fracture in postmenopausal osteoporosis. Cessation of denosumab therapy however is associated with rapid declines in bone mineral density (BMD), rises in bone rem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9d5d153ea94c81ba754443a6e535f42e
https://doi.org/10.21203/rs.3.rs-1739222/v1
https://doi.org/10.21203/rs.3.rs-1739222/v1
Autor:
Mona Qutub, Aliya Khan, Sharjil Hussain, Ismail Hweija, Heather Zariffeh, Shawn K Davison, Romanovschi Mihai, Iman M’Hiri, Hajar Abu Alrob, Hafsa Haneef, Hosay Said, Salman Iqbal
Publikováno v:
Journal of the Endocrine Society
Introduction: Denosumab, a fully human monoclonal antibody to RANK-ligand, has been shown to increase bone mineral density (BMD) and reduce the risk of hip, vertebral and non-vertebral fractures in postmenopausal women with osteoporosis (1-3). Varyin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79567c7ccc4393c493b04d6cc11234b4
https://doi.org/10.1210/jendso/bvaa046.1431
https://doi.org/10.1210/jendso/bvaa046.1431
Publikováno v:
Journal of the Endocrine Society
Introduction: Denosumab, a fully human monoclonal antibody to RANK-ligand, has been shown to increase bone mineral density (BMD) and reduce the risk of fracture in postmenopausal women with osteoporosis. Cessation of denosumab is associated with rise
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f50575ea13514f98b672d4faaab92e6a
http://europepmc.org/articles/PMC8090192
http://europepmc.org/articles/PMC8090192